Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Wallace Hunter Baldwin"'
Autor:
Seema R. Patel, Taran S. Lundgren, Wallace Hunter Baldwin, Courtney Cox, Ernest T. Parker, John F. Healey, Ryan P. Jajosky, Patricia E. Zerra, Cassandra D. Josephson, Christopher B. Doering, Sean R. Stowell, Shannon L. Meeks
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germi
Externí odkaz:
https://doaj.org/article/470104dc411c45558fc574d5808a9c73
Autor:
Patricia E. Zerra, Ernest T. Parker, Wallace Hunter Baldwin, John F. Healey, Seema R. Patel, James W. McCoy, Courtney Cox, Sean R. Stowell, Shannon L. Meeks
Publikováno v:
Biomedicines, Vol 10, Iss 7, p 1724 (2022)
The development of anti-drug antibodies represents a significant barrier to the utilization of protein-based therapies for a wide variety of diseases. While the rate of antibody formation can vary depending on the therapeutic employed and the target
Externí odkaz:
https://doaj.org/article/ce4692653e9c4e57872dea79388e30ad
Autor:
Ernest T. Parker, John F. Healey, Wallace Hunter Baldwin, Glaivy Batsuli, Shannon L. Meeks, Pete Lollar, R. Mercer, Courtney Cox, Jasmine Ito
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 16(9)
Essentials Inhibitor formation remains a challenging complication of hemophilia A care. The Bethesda assay is the primary method used for determining bleeding risk and management. Antibodies that block factor VIII binding to von Willebrand factor can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff8900c7a9bcdcee3448ae39c654619
https://pubmed.ncbi.nlm.nih.gov/29981270
https://pubmed.ncbi.nlm.nih.gov/29981270
Autor:
Ernest T. Parker, John F. Healey, Glaivy Batsuli, Seema R. Patel, Shannon L. Meeks, Wallace Hunter Baldwin, Courtney Cox
Publikováno v:
Blood. 134:1109-1109
Introduction: Though a vital therapy for patients with hemophilia A, exposure to factor VIII (fVIII) can lead to the development of neutralizing anti-fVIII IgG. Interestingly, not all patients with hemophilia A form inhibitors, with approximately 20-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99825b68dc13aa12f36e737f05f02247
https://doi.org/10.1182/blood-2019-130890
https://doi.org/10.1182/blood-2019-130890
Autor:
Glaivy Batsuli, John S. Lollar, Courtney Cox, Shannon L. Meeks, Wallace Hunter Baldwin, Seema R. Patel
Publikováno v:
Blood. 134:2387-2387
Introduction: The immune response to factor VIII (fVIII) is a CD4+ T cell dependent process initiated by fVIII recognition and processing by antigen presenting cells. The C1 and C2 domains have been proposed as the primary domains that mediate fVIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abd47df642647d64fcd3180b944c79d3
https://doi.org/10.1182/blood-2019-127436
https://doi.org/10.1182/blood-2019-127436
Autor:
Michael J. Lenardo, Chrysi Kanellopoulou, Ping Jiang, Shannon L. Meeks, Pete Lollar, Ernest T. Parker, Courtney Cox, Brittany Chao, John F. Healey, Kimberly Shafer-Weaver, Wallace Hunter Baldwin
UNLABELLED ESSENTIALS: Anti-factor VIII (FVIII) inhibitory antibody formation is a severe complication in hemophilia A therapy. We genetically engineered and characterized a mouse model with complete deletion of the F8 coding region. F8(TKO) mice exh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2025715604fb7373b0aa6f68330d46
https://europepmc.org/articles/PMC4755856/
https://europepmc.org/articles/PMC4755856/
Autor:
Pete Lollar, Courtney Cox, Glaivy Batsuli, Shannon L. Meeks, Ernest T. Parker, Wallace Hunter Baldwin, John F. Healey
Publikováno v:
Blood. 128:3762-3762
Introduction: Dendritic cells are the predominant antigen presenting cells (APCs) responsible for recognition and processing of pathogens and other proteins to induce a primary immune response. Factor VIII (FVIII) is a highly immunogenic protein and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2d21983a49f1e27ce5e359dab9f92f2
https://doi.org/10.1182/blood.v128.22.3762.3762
https://doi.org/10.1182/blood.v128.22.3762.3762
Publikováno v:
Blood. 128:3772-3772
Introduction: Up to 30% of patients with severe hemophilia A will develop inhibitory antibodies to factor VIII (fVIII inhibitors). Patients with congenital hemophilia who develop inhibitors usually have a polyclonal antibody response directed against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4361160d103fa382795a87ff962d2e
https://doi.org/10.1182/blood.v128.22.3772.3772
https://doi.org/10.1182/blood.v128.22.3772.3772
Autor:
Wallace Hunter Baldwin, Pete Lollar, John F. Healey, Glaivy Batsuli, Shannon L. Meeks, Brenda Nguyen, Courtney Cox, Ernest T. Parker
Publikováno v:
Blood. 126:1066-1066
Introduction: Hemophilia A is an X-linked bleeding disorder characterized by a deficiency or absence of blood coagulation protein factor VIII (fVIII). Inhibitor development is the most common complication of fVIII treatment occurring in up to 30% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::179ae9e1989d614b3c5144d637af0f2d
https://doi.org/10.1182/blood.v126.23.1066.1066
https://doi.org/10.1182/blood.v126.23.1066.1066
Autor:
Wallace Hunter Baldwin, Margaret A. Robinson, Shannon L. Meeks, Courtney Cox, Philip M. Zakas
Publikováno v:
Blood. 124:2837-2837
The most significant complication in the management of patients with hemophilia A continues to be the development of anti-factor VIII antibodies in response to infusions of the fVIII protein. Patients with hemophilia A typically develop a polyclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16c2c1d4b2a4a8813d5a4e011bd8e4ed
https://doi.org/10.1182/blood.v124.21.2837.2837
https://doi.org/10.1182/blood.v124.21.2837.2837